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Chronic Obstructive Pulmonary Disease (COPD) impairs quality of life and presents symptoms
that affect the lives of patients. Our study analysed the degree of concordance between the
patients and their pulmonologists in the perception of the severity of symptoms. A cross-
sectional, descriptive, multicentre study was conducted in patients with COPD. From a list
of 10 symptoms (cough, dry mouth, chest pain, expectoration, wheezing/whistling in the
lungs, depression/sadness/discouragement, fatigue/tiredness/general lack of energy, anxi-
ety/nervousness, breathlessness/shortness of breath upon exertion and difficulty sleeping/
sleep disorders) each investigator and patient assessed those which, in their opinion, most
concerned or affected the patient. A total of 450 patients were included in the study
(91.3% males, 66.7 years old (SDZ 10.2), FEV1(%) 51.7% (SDZ 12.7%)). At an aggregate level,
breathlessness/shortness of breath, fatigue/tiredness and coughing were identified by pa-
tients and physicians as being the most relevant symptoms. However, according to the concor-
dance analysis conducted with individual pairs (each pulmonologist with his/her patient), only
52.8% coincided when identifying the symptom that most concerned or affected the life of the
patient. The concordance analysed by the Kappa index between patients and physicians was
poor (<0.42). The degree of physicianepatient concordance was greater in patients with moreeumologia, Hospital General Universitari Vall d’Hebron, Pg. Vall d’Hebron 119-139, 08035 Barcelona,
ron.net (M. Miravitlles).
3 Elsevier Ltd. All rights reserved.
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1978 M. Miravitlles et al.severe COPD. The patients and their pulmonologists identified the same three main symptoms
of COPD but showed low concordance when assessing the impact of the symptoms of the
illness.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) produces a
very relevant impact on the general well-being and quality
of life of the patient who suffers from it [1,2]. Besides the
known symptoms of the disease there are other aspects
such as fatigue or sleep disorders that present significant
daily challenges for patients with COPD, even though they
may go unnoticed by the physician [3e5]. The cause of this
lack of adequate recognition may lie in the physician
interpreting these symptoms differently from the way the
patient perceives them, and consequently may not give
these symptoms the due importance in his/her clinical
monitoring.
This differential perception of symptoms between the
physician and the patient, within different health areas,
has been named physicianepatient concordance, and has
generated growing interest in recent years. This is due to
progressive changes within the healthcare model, giving
greater importance to the patient and his/her opinion
regarding the treatment of their disease and the healthcare
they receive. Physicianepatient concordance has been the
subject of studies on such diverse aspects as patient quality
of life [6], patient satisfaction regarding certain aspects of
healthcare [7], symptomatic manifestations specific to
certain populations such as elderly patients [8], primary
care patients [9,10] and symptomatic manifestations asso-
ciated with certain diseases such as cancer [11]. Generally
speaking, these aspects have yielded low levels of concor-
dance in terms of perception, which may reflect a problem
in the physicianepatient relationship and, consequently, in
the monitoring of the illness.
So far the few studies on “physicianepatient” concor-
dance centred on the area of COPD have been exploratory
in nature, with small sample sizes providing insufficient
information [12,13]. However, to what extent the percep-
tion of the physician and the patient differs or agrees, with
regard to the level of symptoms caused by COPD, would
provide new knowledge that could help to more precisely
identify the healthcare needs of the patient.
The present study proposes to quantify and compare the
relative importance attributed by the patients as well as
the specialists, who regularly attend them, with regard to
certain symptomatic manifestations relating to COPD. It
seeks to highlight the commonalities and differences be-
tween the perceptions of the physician and the patient
with respect to a common reality.
Methods
This was a multicentre, observational, cross-sectional,
descriptive study conducted in the Pneumology Servicesin hospitals throughout Spain. Information gathering was
conducted during a single visit in which the principal
sources of information were the patients themselves, along
with their corresponding clinical histories and their
physicians.
The patients included in the study had to comply with
the following criteria: a) a diagnosis of moderate or severe
COPD (post-bronchodilator FEV1/FVC <0.70 and FEV1(%)
<80%); b) age 40 years old; c) smoker or ex-smoker of at
least 10 pack-years; d) patients who were capable of un-
derstanding and filling out the questionnaires; and e) pa-
tients that had signed the informed consent form to take
part in the study.
Those not included in the study were: a) patients diag-
nosed with another chronic respiratory disease such as
asthma or any serious comorbidity that might affect the
interpretation of the outcomes, including sleep apnoea
syndrome, uncontrolled cancer, symptomatic heart failure,
dementia, depression, alcoholism or other addictions and
moderate or severe kidney failure; b) hospitalised patients;
c) patients who were taking part in any other clinical trial
or research study; d) patients with COPD exacerbation at
the time of inclusion; and e) patients requiring continuous
oxygen therapy. The study was approved by the Clinical
Ethics and Research Committee (CIEC) of the Hospital
Universitari Vall d’Hebron (Barcelona, Spain) and all the
patients gave written informed consent.
Data collection for the study was conducted between
July and November 2008. During a single visit with the
pulmonologist, each patient provided socio-demographic
data (age, sex, level of education) and clinical data related
to COPD (time since diagnosis, spirometry with bronchodi-
lator test, smoking habits, COPD clinical symptoms, phar-
macological treatment, comorbidity). The degree of
dyspnoea was evaluated with the Medical Research Coun-
cil’s (MRC) scale [14]. Comorbidity was evaluated using the
Charlson Index [15].
An ad-hoc list was prepared for the study that included
the following COPD symptoms: cough, dry mouth, chest
pain, expectoration, wheezing/whistling in the lungs,
depression/sadness/discouragement, fatigue/tiredness/
general lack of energy, anxiety/nervousness, breathless-
ness/shortness of breath upon exertion and difficulty
sleeping/sleep disorders. For each patient, the investigator
identified the four symptoms that in his/her opinion most
concerned or affected the patient’s life at that time,
scoring the symptoms from the greatest to the least
impact. At the same time, the patient also indicated which
4 of the 10 symptoms affected him/her most. Moreover, the
patient also evaluated the impact of the 10 symptoms on
his/her daily life and how they were affected by means of a
Likert-type ordinal scale of 5 response options ranging from
“It doesn’t affect me” to “It affects me a lot”. The
Table 1 Socio-demographic and clinical characteristics of
the study sample (N Z 450).
Age, mean (SD) 66.7 (10.2)
Sex, male, N (%) 411 (91.3)
Level of education, N (%)
No formal education 88 (19.6)
Primary education 237 (52.7)
Secondary education 88 (19.6)
University or similar 35 (7.8)
Time (in years) since
diagnosis, mean (SD)
7.7 (5.3)
Post-bronchodilator
spirometry values, mean (SD)
FVC (ml) 2836.8 (720.9)
FVC (%) 77.3 (17.4)
FEV1 (ml) 1470 (449.5)
FEV1 (%) 51.7 (12.7)
FEV1/FVC 51.1 (10)
Smoking, N (%)
Ex-smoker 346 (76.9)
Smoker 101 (22.4)
Pack-years, mean (SD) 49 (26.6)
Degree of dyspnoea, mean (SD) 2.5 (0.8)
Exacerbations in
the last 12 months,
mean (SD) [min, max]
1.67 (1.83)
[0, 13]
Pharmacological treatment, N (%)
Short acting beta 2 agonist 259 (57.5)
Long acting beta 2 agonist 390 (86.6)
Inhaled corticosteroids 374 (83.1)
Oral corticosteroids 10 (2.2)
Anticholinergics 383 (85.1)
Theophylline 38 (8.4)
Number of treatments
indicated for COPD,
mean (SD)
3.2 (1.04)
Number of concomitant
treatments, mean (SD)
1.1 (1.4)
Charlson comorbidity
index, mean (SD)
1.8 (2.7)
SD: standard deviation.
Perception of symptoms among COPD patients and physicians 1979assessment of the symptoms by the physician and the pa-
tient were conducted simultaneously and without the
likelihood of interaction between the two. Questionnaires
for patients and physicians had a different structure and
design to make direct comparisons difficult in an attempt to
prevent any potential biased responses.
Lastly, data relative to the study investigator was also
collected, in particular: his/her age, sex, years of practice
as a specialist, practice setting, monthly average of COPD
cases he/she diagnosed as well as the average monthly
number of COPD cases attended, for the purpose of
assessing whether or not there was any kind of association
between the level of concordance and the profile of the
investigator.
Statistical analysis
Categorical variables have been described according to the
number and percentage of subjects in each category.
Continuous variables have been described using mean and
standard deviation. Non-parametric tests (bilateral Kol-
mogoroveSmirnov tests with a confidence level of 95%)
were conducted to assess the normal distribution of the
questionnaire scores; therefore the bivariate analysis was
carried out using the ManneWhitney test (for two samples),
the bilateral KruskaleWallis test with a confidence level of
95% (for ‘n’ samples) and Spearman Rho (for continuous
variables). The use of these three non-parametric tests was
determined on a case-by-case basis. The bivariate analyses
between variables with normal distribution were conducted
by means of the unilateral Fisher’s Exact Test or the
bilateral Chi-Square Test, both with a confidence level of
95%. In addition, the Kappa index [16] was obtained to
assess the degree of concordance between two different
observers (patient and physician) in order to assess to what
extent Observer 1 and Observer 2 coincided in their mea-
surement or assessment when using categorical variables.
In this case, this index was used to measure the degree of
concordance between the patient and his/her physician in
identifying which of the 10 COPD symptoms studied con-
cerns or affects the patient’s life the most. The magnitude
of the K coefficient, which ranges from 0 (without concor-
dance) to 1 (maximum concordance) is usually interpreted
as follows: poor concordance (K < 0.20), weak concordance
(K between 0.21 and 0.40), moderate concordance (K be-
tween 0.41 and 0.60), good concordance (K between 0.61
and 0.80), and very good concordance (K between 0.81 and
1.00) [17]. Statistical analysis were carried out using spe-
cific SPSS software.
Results
A total of 77 pulmonologists from 63 hospitals evaluated
649 candidate patients to be enrolled in the study. Of
these, 152 were excluded for non-compliance with any one
of the inclusion or exclusion criteria and 47 for possessing
insufficient data for analysis, so that the final evaluable
sample consisted of 450 cases (69.3%).
Table 1 shows the socio-demographic and clinical char-
acteristics of the patients included. There was a majority of
males (91.3%) with a mean age of 66.7 years (SD Z 10.2)and with a low or very low level of education (72.3%). The
mean time since diagnosis of the illness was 7.7 years
(SD Z 5.3). The mean FEV1(%) post-bronchodilator was
51.7% (SD Z 12.7%). 76.9% were ex-smokers with a mean
tobacco consumption of 49 (SD Z 26.6) pack-years. The
mean degree of dyspnoea was 2.5 (SD Z 0.8). The most
used medication was long-acting beta 2 agonists (86.6%),
anticholinergics (85.1%) and inhaled corticosteroids
(83.1%). The mean Charlson index was 1.8 (SD Z 2.7).
Table 2 shows the list of COPD symptoms which, ac-
cording to both physicians and patients, most affected
patients’ lives. In general, the group of patients and phy-
sicians identified “breathlessness/shortness of breath upon
exertion” as the symptom that most concerned or affected
patients’ lives, followed by “fatigue/tiredness/general lack
of energy” and “cough”. From there on patients and phy-
sicians differed in opinion. For example, according to
Table 2 Ranking of COPD symptoms that affect or concerna the study patients, according to the physician and according to
the patient (N Z 450).
Patient’s assessment Physician’s assessment Spearman’s
Rho
Difference in
meansbPosition
in the
ranking
Mean
(SD)
Position
in the
ranking
Mean
(SD)
Breathlessness/shortness
of breath upon exertion
1st 2.58 (1.04) 1st 3.05 (1.34) 0.29 <0.001
Fatigue, tiredness,
lack of energy in general
2nd 2.23 (1.15) 2nd 1.67 (1.46) 0.30 <0.001
Coughing 3rd 1.81 (1.11) 3rd 1.53 (1.41) 0.29 <0.001
Anxiety/nervousness 4th 1.57 (1.27) 7th 0.49 (1.03) 0.34 <0.001
Expectoration 5th 1.56 (1.09) 4th 1.05 (1.28) 0.36 <0.001
Dry mouth 6th 1.45 (1.32) 9th 0.35 (0.94) 0.27 <0.001
Despondency, sadness
or enervation
7th 1.43 (1.24) 5th 0.63 (1.13) 0.36 <0.001
Wheezing/whistling
in the lungs
8th 1.32 (1.07) 6th 0.54 (1.03) 0.25 <0.001
Difficulty sleeping,
sleep disorders
9th 1.32 (1.25) 8th 0.39 (0.90) 0.33 <0.001
Chest pain 10th 0.71 (0.95) 10th 0.19 (0.66) 0.28 <0.001
a The scale used ranges from 0 (doesn’t affect/concern the patient) to 4 (affects or concerns the patient a lot).
b After conducting the KolmogoroveSmirnov test a comparative analysis by means of non-parametric tests was conducted: test for 2
independent samples U Mann Whitney (confidence level of 95%).
1980 M. Miravitlles et al.patients, “anxiety and nervousness” was a symptom that
concerned or affected them somewhat (appearing in 4th
place), while the physicians considered it to be much less
relevant (appearing in 7th position), which means a low
correlation with regard to the importance attributed to
each symptom by both physicians and patients (Spearman
Rho Z 0.29e0.30).
Fig. 1 and Table 3 show the results of the concordance
analysis between the 450 pairs of observers (each patient
with his/her corresponding physician). When asked which
symptom most concerned or affected the patient’s life, 238
pairs of observations coincided (52.8% of the total). In
particular, for 258 patients “Breathlessness/shortness of
breath” was the most distressing symptom. Concurrently,
the physicians considered that this was the symptom that
most concerned 204 of the assessed patients. However,
when analysing these assessments for each pair of physi-
cians/patients, only 159 of the assessments given by the
physicians concurred with those of the patients (Cohen’s
Kappa value of barely 0.37). In terms of “Expectoration”, it
was the most distressing symptom for 24 patients and the
physicians considered this symptom as being the greatest
concern in 25 of the assessed patients. However, only 11 of
these assessments coincided between physician and patient
(Cohen’s Kappa value of 0.42). When conducting a
symptom-by-symptom assessment, Cohen’s Kappa values
ranged between 0.18 and 0.42.
Table 4 describes which characteristics of the patients
and physicians were associated with patientephysician
concordance with respect to identifying the COPD symptom
that most concerns and affects the life of the patient. In
the group of concordant pairs there was a greater fre-
quency of patients with severe COPD (pZ 0.019), patients
with a higher degree of dyspnoea (pZ 0.002), patients withmore exacerbations (p Z 0.026) and those treated in hos-
pitals (pZ 0.046) and ex-smokers (p Z 0.004), than in the
group of non-coinciding patientephysician pairs. This trend
was corroborated when obtaining Cohen’s kappa values
between patientephysician for the “breathlessness/short-
ness of breath” in patients who smoke (kappa Z 0.19) and
ex-smokers (kappa Z 0.42), and in patients with severe
(kappaZ 0.39) and moderate dyspnoea (kappaZ 0.31). At
the same time, the symptom considered as most critical by
both the patient and the physician was “breathlessness/
shortness of breath”, regardless of the degree of COPD
severity (in terms of dyspnoea and stage of illness) and of
whether they were active or ex-smokers.Discussion
The present study was conducted to provide evidence to
identify any similarities or disparities between physicians
and patients in the perception of symptoms and the
severity of COPD, not only from an aggregate perspective,
but more importantly, at the level of inter-observer
concordance; in other words, between each patient and
his corresponding physician. As is shown in some other
studies conducted in other therapeutic areas [18,19],
patientephysician concordance could be vital in contrib-
uting to improved control of the patient’s disease, amongst
other things, because it would serve to adapt clinical
management and treatment to the needs of each individual
patient. On the other hand, poor concordance would
encourage the physician to make decisions that did not
conform to the patient’s reality. The recently published
Spanish guidelines [20e22] and the new GOLD document
[23] recommend and insist on including symptom severity
Figure 1 Degree of physicianepatient concordance to identify which COPD symptom most affects the life of the patient
(N Z 450).
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Assessment Test (CAT) and the COPD Clinical Questionnaire
(CCQ) in the new recommendations is an attempt to
improve patientephysician communication, but their
implementation in primary care in most countries is still
very limited. The results of this study shed more light upon
the little data available at the present time, with regard to
the degree of patientephysician concordance within the
scope of COPD [12,13] for the purpose of designing poten-
tial remedial strategies.
According to the study results, at the aggregate-level,
both the participating patients and physicians coincided in
considering that breathlessness/shortness of breath, fa-
tigue/tiredness and cough, in this order, were the three
symptoms that most concerned and affected the lives of
patients with COPD. However, a detailed analysis of the
concordance between each patient and his/her physician
suggests that the office visit with the pulmonologist does
not provide a sufficiently precise idea of the impact of the
symptoms on the patient’s life. This is true, if we bear in
mind that barely 53% of the physicians were correct in
identifying the symptom that most concerned or affectedeach patient’s life. In fact, the same occurred when the
concordance analysis was conducted differentially for the
10 assessed symptoms: in both the 5 patients who consid-
ered chest pain to be the symptom that most concerned
them and the 258 patients that considered breathlessness/
shortness of breath to be the most distressing symptom, the
physician’s rate of accuracy was poor, obtaining concor-
dance indexes of less than 0.42. There was a tendency for
greater concordance when the symptom referred to as the
most critical for the patient could be detected as a sign the
diagnosis of the disease (for example breathlessness,
coughing, expectoration or wheezing) instead of being
more subjective (as in nervousness, anxiety, fatigue or dry
mouth).
There are very few studies dealing with patient-
ephysician communication in the field of COPD. A previous
study performed in the US in a population of 342 veterans
with COPD showed that better communication between
patients and clinicians was associated with quality of care
and confidence in dealing with breathing problems and the
specific clinicians’ behaviours, with larger associations with
higher quality care including listening, caring and
Table 3 Degree of concordance between physicianepatient when identifying the COPD symptom that most affects the
patient’s life (N Z 450).
Symptom that most concerns or affects the patient’s life at the moment
According
to the
patient, N(%)
According
to the
physician, N(%)
Coincidence between
both observers, N(%)
Kappa index
between assessors
Coughing 49 (10.9) 41 (9.1) 20 (4.4) 0.383
Dry mouth 14 (3.1) 20 (4.4) 6 (1.3) 0.328
Chest pain 5 (1.1) 8 (1.8) 2 (0.4) 0.298
Expectoration 24 (5.3) 25 (5.6) 11 (2.4) 0.417
Wheezing/whistling
in the lungs
13 (2.9) 20 (4.4) 7 (1.6) 0.403
Despondency,
sadness or enervation
20 (4.4) 17 (3.8) 8 (1.8) 0.408
Fatigue, tiredness,
lack of energy in general
48 (10.7) 75 (16.7) 17 (3.7) 0.183
Anxiety, nervousness 12 (2.7) 21 (4.7) 4 (0.9) 0.216
Breathlessness,
shortness of breath
upon exertion
258 (57.3) 204 (45.3) 159 (35.3) 0.369
Difficulty sleeping,
sleep disorders
7 (1.6) 19 (4.2) 4 (0.9) 0.292
Total 450 (100%) 450 (100%) 238 (52.8)
Table 4 Clinical characteristics of the patient according to the degree of concordance with his physician regarding the
symptom that most concerns him/affects his life (N Z 450).
Degree of concordance between the two observers
(physician and patient)
p-Value
With concordance
(N Z 238)
Without concordance
(N Z 212)
Years of evolution of COPD, mean (SD) 7.9 (5.3) 7.4 (5.4) 0.315a
Stage of the illness, N (%)
Moderate 117 (48.3) 125 (51.7) 0.019b
Severe 119 (58.6) 84 (41.4)
Degree of dyspnoea, mean (SD)
0e1 103 (45.6) 123 (54.4) 0.002b
2e4 132 (59.7) 89 (40.3)
Number of outpatient treated
exacerbations, in the
last 12 months, mean (SD)
1.2 (1.3) 1 (1.2) 0.071a
Number of exacerbations
requiring hospital
admission, in the
last 12 months, mean (SD)
0.6 (1) 0.5 (1.4) 0.046a
Total number of
exacerbations, mean (SD)
1.8 (1.8) 1.5 (1.9) 0.026a
Charlson’s index
of comorbidities, mean (SD)
1.6 (2.7) 1.9 (2.8) 0.298a
Currently a smoker, N (%)
No 195 (56.4) 151 (43.6) 0.004b
Yes 41 (40.6) 60 (59.4)
a ManneWhitney non-parametric bilateral test for two independent samples (confidence level of 95%).
b Fisher’s Exact unilateral test (level of confidence 95%).
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patients and their physicians has different explanations.
One reason is the absence of a systematic procedure to
assess the patient’s symptomatology during the clinical
visit. The absence of a list of questions encourages the
omission of relevant symptomatic aspects. On the other
hand, even if the physician does not formulate a question,
the patient can explain the symptoms that affect him/her,
but this spontaneous explanation on behalf of the patient
will vary according to the planning of the visit, memory and
personal and emotional factors. The time that the physician
can devote to the patient during an office visit is also
another factor to be borne in mind. Therefore, a symptom
that may concern the patient could be passed over during a
rushed visit. Moreover, the fact that on many occasions the
patients treated are stable and/or long-term ones instead
of recently diagnosed patients would contribute to the of-
fice visits being more routine and would induce a certain
assimilation on the patient’s behalf of what his illness is and
what COPD means, which would lead to a lesser predispo-
sition to explain any changes in the symptoms suffered [8].
A “fair” degree of concordance was observed when the
patient presented severe versus moderate COPD, when the
dyspnoea levels are worse and the patient has a greater
number of exacerbations or hospitalisations. These factors
have also been identified in previous studies about other
diseases [8,11] and their influence on concordance could be
put down to the physician attending these seriously ill pa-
tients more often and therefore being more informed about
their status. Moreover, it is reasonable to believe that pa-
tients with more advanced COPD experience more abun-
dant and intense symptoms and, therefore, these are more
easily described by the patient and recognisable to the
physician. It can also be assumed that as COPD advances,
the patient will more openly express anything relating to
the illness and how he/she deals with it on a day-to-day
basis, so that patientephysician communication will be
more effective and sincere. All this is consistent with pre-
vious studies, according to which patientephysician
communication is associated with the quality of the health
care received [24]. Therefore, strategies to promote this
therapeutic communication could positively affect the care
received by patients with COPD.
Lastly, when the patient is an ex-smoker versus a
smoker, patientephysician concordance also improves
somewhat. The negative influence of active smoking within
concordance is probably due to the patient’s awareness of
not following the physician’s indications or recommenda-
tions, which may sway him/her towards secrecy and the
tendency to underestimate the symptoms.
The study also presents some limitations to be consid-
ered. On the one hand, the participating physicians were
aware of the objectives of the study being conducted,
meaning that they may have made a special effort to make
assessments that coincided in great part with the patient’s
perceptions. However, because of this, the study results
acquire greater relevance with regard to the discrepancies
between patients and physicians. Another limitation to be
borne in mind is that the study was conducted in the field of
outpatient hospital care by pulmonologists. We do not know
if these results can be extrapolated to other fields such as
out-patient primary care centres, where the time availablefor attending to patients may be even more limited. We
used a questionnaire developed ad hoc for the purpose of
the study. This questionnaire did not follow any formal
validation process because it was not intended to be used
for any scoring system or guiding in any management de-
cisions. Comorbidities may have influenced the intensity
and perception of symptoms; however, we only focused on
the concordance between patients and clinicians in the
interpretation of symptoms irrespective of the causes.
Finally, another limitation is the low number of female
patients. The gender distribution in our study corresponds
to the gender distribution of COPD in Spain where most
patients with moderate to severe COPD are males [2].
Therefore, extrapolation to women must be made with
caution.
In conclusion, although patients and clinicians identified
the same three main symptoms of COPD, this study provides
further evidence regarding the low level of concordance
existing between the COPD patient and the physician at the
time of assessing the impact of disease symptoms on the
patient’s life, although this concordance was higher when
the case assessed presented more severe disease. In light of
these results, it would be recommendable to define stra-
tegies to encourage specialists to take a closer and more
accurate view of the impact of the symptoms of the disease
on the patient’s life and adapt it to the clinical manage-
ment of the patient’s reality as much as possible.List of researchers (by alphabetical order)
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